Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

From singing on Broadway to playing beloved characters on the big screen (including everyone's favorite animated snowman, ...

By now, you likely know which foods and drinks can help prevent Type 2 diabetes—but did you know that the order in which you ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Health experts are concerned Ozempic and other GLP-1 agonist drugs may be inappropriately prescribed to people experiencing disordered eating.

ANAHEIM, CALIF. — Evolving consumer need states combined with unpredictable economic factors are changing the way snack manufacturers interact with customers today, according to a panel of snack ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Many are in the chase of quick fixes in weight loss, but more than often it's ineffective. Expert debunks 6 common weight loss myths.

Evoke Pharma, Inc. ( NASDAQ: EVOK) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Daniel Kontoh-Boateng – DKB Partners Matt D’Onofrio – Chief Executive Officer Chris Quesenberry – Chief ...